• PDF / 174,068 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 87 Downloads / 151 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: case report In a case series, a 28-year-old man developed Clostridium difficile infection and a 62-year-old man developed Pseudomonas aeruginosa sepsis, and Pseudomonas aeruginosa and Candida albicans lung abscesses during off-label treatment with eculizumab and tocilizumab for COVID-19 [outcomes not stated]. Case 6 from the article: The 28-year-old man was admitted with dry cough, fever, myalgias, diarrhoea and increasing dyspnoea on exertion. He was eventually diagnosed with critical COVID-19. Subsequently, he started receiving off-label hydroxychloroquine 600mg every 12 hours for 1 day, followed by 400mg every 12 hours for 4 days. He also received prophylactic anticoagulation with enoxaparin sodium. Later on, he was found to have developed respiratory failure and acute kidney injury, and the D-dimer was found to be elevated. On day 6 of hospitalisation, the dyspnoea progressively increased, and mechanical ventilation was thus initiated. Also, off-label treatment with IV tocilizumab infusion 800mg was initiated, along with IV remdesivir 5 mg/kg daily (for 10 days). Additionally, the anticoagulation was switched to a therapeutic dose of enoxaparin sodium. By day 14 of hospitalisation, his D-dimers got stabilised. A biopsy of a normal-appearing deltoid skin showed significant micro-vascular deposits of C5b-9, C4d and MASP2. Thereafter, he received unspecified vaccine for Neisseria meningitides, and maintained on unspecified prophylactic antibiotics. He also received off-label IV eculizumab infusion 900mg. However, he developed Clostridium difficile infection during the course of treatment. Levofloxacin was thus added to the various ongoing antibiotics, which were being administered due to an occult infection and persistent pneumothorax. The drug therapy of eculizumab and tocilizumab were determined to be risk factors for development of Clostridium difficile infection. His FiO2 requirements lessened gradually; however, in view of persistent infections, additional doses of eculizumab were not administered. In the 14 week of hospitalisation, he died [cause of death not stated]. Case 9 from the article: The 62-year-old man, who was hospitalised due to dry cough, fever, chills and progressive dyspnoea, was eventually diagnosed with critical COVID-19. Subsequently, he started receiving off-label hydroxychloroquine 600mg every 12 hours for 1 day, followed by 400mg every 12 hours (scheduled for 4 days) and off-label IV remdesivir 5 mg/kg daily (for 10 days). He also received prophylactic anticoagulation with enoxaparin sodium. Later on, he developed respiratory failure and acute kidney injury, and the D-dimer was also found to be elevated. On day 4, increasing dyspnoea was noted, requiring mechanical ventilation and unspecified vasopressors support. On day 7 of hospitalisation, he started receiving off-label IV tocilizumab infusion 400mg. On day 9, therapeutic dose of enoxaparin sodium was initiated. On day 11, he developed atrial fibrillation [aetiology not stated], for which amiodarone was initia